Key Takeaways
- GSK (GSK) significantly exceeded Q3 2025 earnings expectations, with revenue reaching £8.55B against an estimated £8.28B, driven by exceptional vaccine sales, particularly Shingrix and Arexvy.
- UBS (UBS) reported a substantial 74% increase in quarterly profit, fueled by robust client inflows, indicating strong performance in its banking operations.
- Mercedes-Benz (MBG) confirmed its full-year guidance despite tariffs and weakness in the Chinese market weighing on its latest earnings results.
Pharmaceutical giant GSK (GSK) delivered a stellar performance in the third quarter of 2025, surpassing analyst estimates across key financial metrics. The company reported total revenue of £8.55 billion, comfortably beating the estimated £8.28 billion. This strong showing was largely propelled by its Vaccines division, which posted £2.68 billion in revenue against an estimated £2.6 billion.
A standout performer was Shingrix, with revenue hitting £830 million compared to an estimated £727 million, alongside Arexvy which generated £251 million, significantly above the £180.2 million estimate. GSK (GSK) also reported an adjusted EPS of 55p, exceeding the 47p estimate, and declared a dividend per share of 16p, higher than the anticipated 15p. The company now foresees an improved outlook for its full-year adjusted operating profit.
In the financial sector, UBS (UBS) announced a robust 74% rise in its quarterly profit, according to reports from the Financial Times. This substantial increase was attributed to strong client inflows, signaling healthy growth and confidence in the bank's services.
Meanwhile, German automotive powerhouse Mercedes-Benz (MBG) confirmed its financial guidance for the year, even as tariffs and softness in the Chinese market impacted its recent earnings. The Wall Street Journal reported that despite these headwinds, the company remains confident in its outlook. This indicates Mercedes-Benz (MBG) is navigating a challenging global economic landscape while maintaining its strategic targets.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.